MedTrace Logo

SAR447971 First-in-human Study

NCT07629336 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2026-06-05

No results posted yet for this study

Summary

SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.

MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants.

MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants.

Number of participants - The total expected number of healthy participants is approximately 94 and the total number of HS participants is expected to be approximately 20.

* SAD20411 will enroll up to 46 participants
* MAD20412 will enroll up to 48 participants
* MAD24339 will enroll up to 20 participants

Duration of study - The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.

Conditions

  • Hidradenitis
  • Healthy Volunteers

Interventions

DRUG

SAR447971

Pharmaceutical form: Tablet Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Tablet Route of administration: Oral

Sponsors & Collaborators

  • Kymera Therapeutics, Inc.

    collaborator INDUSTRY

  • Sanofi

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-26
Primary Completion
2028-02-16
Completion
2028-02-16

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629336 on ClinicalTrials.gov